<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511820</url>
  </required_header>
  <id_info>
    <org_study_id>TTYLA1201</org_study_id>
    <nct_id>NCT03511820</nct_id>
  </id_info>
  <brief_title>A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever</brief_title>
  <official_title>A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TTY Biopharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amphotericin B is a polyene antifungal drug used for the treatment of many systemic fungal&#xD;
      infections. It is associated with many side effects which in some cases can be very severe&#xD;
      and potentially lethal. Lipo-AB® is a true single bilayer liposomal drug delivery system,&#xD;
      consisting of unilamellar bilayer liposomes with amphotericin B intercalated within the&#xD;
      membrane. Prior studies showed that the liposomal formulation of amphotericin B greatly&#xD;
      reduces the side effects of the parent drug, such as nephrotoxicity. This study is designed&#xD;
      to evaluate the safety and efficacy of Lipo-AB® in neutropenic patients with persistent fever&#xD;
      in routine clinical practice in Taiwan.&#xD;
&#xD;
        1. Primary objective:&#xD;
&#xD;
           • To evaluate the nephrotoxicity of Lipo-AB® (amphotericin B) treatment in neutropenic&#xD;
           patients with persistent fever in Taiwan clinical practice.&#xD;
&#xD;
        2. Secondary objectives:&#xD;
&#xD;
      (1) To evaluate the safety profile of Lipo-AB® (amphotericin B) in neutropenic patients with&#xD;
      persistent fever in Taiwan clinical practice.&#xD;
&#xD;
      (2) To evaluate the treatment efficacy of Lipo-AB® (amphotericin B) in neutropenic patients&#xD;
      with persistent fever in Taiwan clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2016</start_date>
  <completion_date type="Actual">January 15, 2018</completion_date>
  <primary_completion_date type="Actual">January 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of nephrotoxicity</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>* Nephrotoxicity is defined as serum creatinine (SCr) values increasing 100% or more over pretreatment levels in pediatric patients, and creatinine values increasing 100% or more over pretreatment levels in adult patients provided the peak creatinine concentration was &gt; 1.2 mg/dL during treatment period.&#xD;
** The nephrotoxicity associated with baseline SCr will also be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorization of the change in renal function</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>SCr &lt; 1.5 x baseline SCr (BSC)&#xD;
SCr ≥ 1.5 x BSC&#xD;
SCr ≥ 2 x BSC&#xD;
SCr ≥ 3 x BSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (1)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>hemoglobin (Hb in g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (2)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>hematocrit (Hct in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (3)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>red blood cell (RBC in 10^6/uL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (4)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>white blood cell (WBC in 10^3/uL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (5)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>ANC (absolute neutrophil count in mm^3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (6)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>platelet count in 10^3/uL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (7)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>alanine aminotransferase (ALT in U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (8)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>aspartate aminotransferase (AST in U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (9)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>total bilirubin (TB in mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (10)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>BUN in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (11)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>serum creatinine (SCr in mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (12)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>glucose (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (13)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>Na (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (14)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>K (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (15)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>Mg (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (16)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>Ca (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in laboratory parameters (17)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>Urine protein (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs (1)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>systolic/diastolic blood pressure (SBP/ DBP in mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs (2)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>pulse rate (PR in bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs (3)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>tympanic temperature (TT in °C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event(s)</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>Hypokalemia, Hypomagnesemia, Hypocalcemia, Hypernatremia, Hyponatremia, Infusion-related reaction(s) (IRR), Other adverse event(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall success rate</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
    <description>Defined as a composite of five criteria:&#xD;
Survival for 7 days after completion of the observational treatment&#xD;
Fever resolved during neutropenic period: defined as a tympanic temperature &lt; 38°C for at least 48 hours&#xD;
Baseline fungal infection cured (if present): defined as (i) resolution of all attributable clinical symptoms and signs of fungal infection during the observational period, (ii) negative microbiological result at the EOT (end of treatment), if available&#xD;
No breakthrough fungal infections (proved, probable and possible) during administration of the observational drug or within 7 days after the completion of observational treatment&#xD;
Absence of premature discontinuation of the observational drug because of toxicity or lack of efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>through Observation period (up to 44 days)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Neutropenia, Febrile</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipo-AB® (amphotericin B) liposome</intervention_name>
    <description>Name: Lipo-AB® (amphotericin B) liposome for injection&#xD;
Dosage form: Lyophilized powder 50 mg/vial&#xD;
Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day&#xD;
Dosing schedule:&#xD;
All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neutropenic patients with persistent fever who are recommended to receive systemic&#xD;
        antifungal therapy based on physician's decision will be invited to participate in this&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or male with no age limit&#xD;
&#xD;
          2. Patient for whom Lipo-AB® is medically recommended due to following conditions:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 500/mm3 for at least 96 hours&#xD;
&#xD;
               -  Received parenteral broad spectrum antibacterial therapy for at least 96 hours&#xD;
&#xD;
               -  Fever of ≥ 38.0°C (tympanic temperature)&#xD;
&#xD;
          3. Subject or his/her legally acceptable representative is willing and able to provide a&#xD;
             written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant female, with the exception of those for whom the possible benefits to be&#xD;
             derived outweigh the potential risks involved&#xD;
&#xD;
          2. Use of other investigational product 2 weeks before the initiation of Lipo-AB®&#xD;
             treatment which is considered not suitable for this study by investigator&#xD;
&#xD;
          3. Use of any parenteral antifungals for current infection which is not considered&#xD;
             treatment failure (either intolerance to the drug or lack of response)&#xD;
&#xD;
          4. Any condition which is considered not suitable for liposomal amphotericin B therapy by&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei city</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11212</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Mucinipal Wanfang Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Guang Memorial Hospital at LinKou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 1, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amphotericin B</keyword>
  <keyword>liposome</keyword>
  <keyword>post marketing surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

